click on circles to display study description...
niraparib (n=138) vs. Standard of Care (SoC) (n=65)
randomized controlled trial
niraparib (300 mg) once daily as maintenance treatment
placebo
ovarian cancer (OC)
double-blind
powered by vis.js Network